Literature DB >> 22931986

Neonatal ventral hippocampal lesion as a valid model of schizophrenia: evidence from sensory gating study.

Xing-Shi Chen1, Chen Zhang, Yi-Feng Xu, Ming-Dao Zhang, Fei-Ying Lou, Chong Chen, Jin Tang.   

Abstract

BACKGROUND: The neonatal ventral hippocampal lesion (NVHL) rat model has been proposed as an experimental model for schizophrenia. NVHL rats display impaired central nervous system (CNS) inhibition, which may lead to a phenomenon similar to P50 sensory gating deficits observed in schizophrenic patients. In this study, we investigated whether sensory gating deficits occurred in the NVHL rat as a model for schizophrenia.
METHODS: We created the NVHL rat model using ibotenate. The P20 and N40 were measured to assess sensory response and gating in NVHL and sham rats. Epidural electrodes recorded evoked potentials (EPs), from which latencies, amplitudes, difference scores (S1-S2), and gating ratios (S2/S1) were assessed.
RESULTS: Compared with sham controls, prolonged S1 N40 latency and decreased S2 N40 amplitude were detected in the NVHL group. In neither difference scores nor gating ratios, a significant difference was found between NVHL group and sham controls.
CONCLUSIONS: NVHL rats may be a valid animal model for schizophrenia. This strategy will be useful in future neurobiological studies investigating the etiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22931986

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  1 in total

1.  Effect on the expression of drd2 and drd3 after neonatal lesion in the lymphocytes, nucleus accumbens, hippocampus and prefrontal cortex: comparative analysis between juvenile and adult Wistar rats.

Authors:  Alma Delia Genis-Mendoza; Carlos Alfonso Tovilla-Zárate; Lilia López-Narvaez; Patricia Mendoza-Lorenzo; Patricia Ostrosky-Wegman; Humberto Nicolini; Thelma Beatriz González-Castro; Yazmin Hernández-Diaz
Journal:  Hereditas       Date:  2016-11-22       Impact factor: 3.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.